7.
LOSS PER SHARE
Basic
and diluted net loss per common share were the same since the inclusion of common shares issuable pursuant to the exercise of options
in the calculation of diluted net loss per common shares would have been antidilutive.
For
the three months ended March 31, 2026 and 2025, loss per share of the Company are as follows:
SCHEDULE OF LOSS PER SHARE
| | |
2026 | | |
2025 | |
| | |
For the Three Months Ended
March 31, | |
| | |
2026 | | |
2025 | |
| Numerator: | |
| | | |
| | |
| Net Loss | |
$ | (485,883 | ) | |
$ | (440,408 | ) |
| Net loss attributable to common shareholders | |
$ | (485,883 | ) | |
$ | (440,408 | ) |
| Denominator: | |
| | | |
| | |
| Weighted-average common shares outstanding, basic and diluted | |
| 16,072,267 | | |
| 12,723,721 | |
| Net loss per common share, basic and diluted | |
$ | (0.03 | ) | |
$ | (0.03 | ) |
The
Company’s potentially dilutive securities, which include stock options and warrants, have been excluded from the computation of
diluted net loss per common share as the effect would be to reduce the net loss per share. Therefore, the weighted-average number of
common shares outstanding used to calculate both basic and diluted net loss per share attributable to common shareholders is the same.
The
Company excluded the following from the computation of diluted net loss per share attributable to common shareholders for the three months
ended March 31, 2026 and 2025 because including them would have had an anti-dilutive effect:
SCHEDULE OF COMPUTATION OF DILUTED NET LOSS PER SHARE
| | |
For the Three
Months Ended | | |
For the Three
Months Ended | |
| | |
March 31, | | |
March 31, | |
| | |
2026 | | |
2025 | |
| Stock options to purchase common stock outstanding | |
| 1,352,279 | | |
| 1,352,279 | |
| Warrants to purchase common stock outstanding | |
| 350,000 | | |
| 350,000 | |
| Total | |
| 1,702,279 | | |
| 1,702,279 | |
| Anti-dilutive shares | |
| 1,702,279 | | |
| 1,702,279 | |
|